IOM Proposals for Overhaul at CIRM Win High Marks
By David Jensen,
California Stem Cell Report
| 12. 07. 2012
[Quotes CGS's Marcy Darnovsky]
The Institute of Medicine's recommendations for major changes at the California stem cell agency today received generally high marks from independent observers and critics.
Many of the proposals echoed suggestions from California's Little Hoover Commission, the state's good government agency. Asked for comment, Stuart Drown, the commission's executive director, said,
“The institute’s recommendations for much-needed changes to CIRM’s governance structure to provide greater efficiency, clarity and accountability reinforce the recommendations the Little Hoover Commission made in 2009."
He continued,
“Then and now, the Commission’s recommendations are aimed at improving
CIRM’s ability to meet its goals for the good of all who can benefit
from stem cell research, and to ensure that California taxpayers’
dollars are put to their most efficient use to that end.”
The California Stem Cell Report also asked the agency's first president,
Zach Hall, for his thoughts. Here is the full text of what Hall, who
was one of the peer reviewers on the IOM study, had to say,
“The IOM Committee and its staff have done an impressive job. The
report recognizes the scientific value and...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...